BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250218
DTEND;VALUE=DATE:20250220
DTSTAMP:20260515T121522
CREATED:20241127T124753Z
LAST-MODIFIED:20241127T124753Z
UID:40158-1739836800-1740009599@www.pharmajournalist.com
SUMMARY:Neuroscience Innovation Pharma Partnering Summit
DESCRIPTION:Significant breakthroughs in CNS biology\, coupled with innovative neuroscience technologies and a more supportive regulatory landscape\, have fueled increased investment and pharmaceutical interest in the CNS. \nWith AbbVie\, BMS\, and Lundbeck making major acquisitions in the last 12 months alone\, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before. \nJoin the Neuroscience Innovation Pharma Partnering Summit to: \n\nConnect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals.\nBuild stronger relationships with key pharma and investor contacts to emphasize your company’s competitive edge\nPosition your company at the front of scientific innovation to show where you add value\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/neuroscience-innovation-pharma-partnering-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250219
DTEND;VALUE=DATE:20250222
DTSTAMP:20260515T121522
CREATED:20241122T121650Z
LAST-MODIFIED:20241122T121650Z
UID:40111-1739923200-1740182399@www.pharmajournalist.com
SUMMARY:3rd Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:In recent industry news\, AAV gene therapies are gaining momentum\, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome\, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market\, valued at $1.5 billion in 2023\, is projected to skyrocket to $22.3 billion by 2029. However\, scaling up production remains a significant challenge\, highlighting the urgency for innovative solutions in viral vector manufacturing.​ \nThe 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston to tackle these challenges head-on. Featuring over 16 expert speakers\, including Yuanli Song\, Associate Director at Sanofi\, the event offers cutting-edge insights into process optimization for viral vector production. Yuanli Song emphasized the importance of this summit\, saying\, “This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production.” \nThe agenda includes two interactive workshops and over 20 hours of insightful content designed to address upstream and downstream challenges\, improve yield\, and enhance scalability. Additionally\, attendees will benefit from 6+ hours of dedicated networking breaks\, fostering collaborations crucial for advancing this field. \nKey topics covered include: \n\nEnhancing capsid ratios and vector optimization\nInnovations in purification techniques\nSeamless tech transfer for scalability\nTackling high-dose production complexities\n\nThis summit is the ultimate opportunity for professionals from companies like Sanofi\, Kite\, Ultragenyx\, and others to stay at the forefront of viral vector manufacturing innovations. With 800+ gene therapy candidates in trials and the FDA’s evolving frameworks\, this event is essential for driving the next wave of scalable\, high–quality therapies​. \nView our agenda to find out more!
URL:http://www.pharmajournalist.com/event/3rd-viral-vector-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR